Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Transplant benefit for patients with hepatocellular carcinoma.

Vitale A, Volk M, Cillo U.

World J Gastroenterol. 2013 Dec 28;19(48):9183-8. doi: 10.3748/wjg.v19.i48.9183. Review.

2.

Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.

Schlansky B, Chen Y, Scott DL, Austin D, Naugler WE.

Liver Transpl. 2014 Sep;20(9):1045-56. doi: 10.1002/lt.23917.

3.

Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.

Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, Everson GT, Hong JC, Terrault N, Hayashi PH, Fisher RA, Everhart JE.

Hepatology. 2011 Oct;54(4):1313-21. doi: 10.1002/hep.24494.

4.

Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma.

Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N.

Liver Transpl. 2011 Oct;17 Suppl 2:S6-13. doi: 10.1002/lt.22423. Review.

5.

Living donor liver transplantation for hepatocellular carcinoma.

Lee SG, Moon DB.

Recent Results Cancer Res. 2013;190:165-79. doi: 10.1007/978-3-642-16037-0_11.

PMID:
22941020
6.

Hepatocellular carcinoma and liver transplantation.

Washburn K, Halff G.

Curr Opin Organ Transplant. 2011 Jun;16(3):297-300. doi: 10.1097/MOT.0b013e3283465756. Review.

PMID:
21505342
7.

A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.

Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, De Carlis L, Belli L, Colledan M, Fagiuoli S, Rossi G, Andorno E, Baccarani U, Regalia E, Vivarelli M, Donataccio M, Cillo U; Liver Transplantation North Italy Transplant program (NITp) working group..

J Hepatol. 2014 Feb;60(2):290-7. doi: 10.1016/j.jhep.2013.10.010. Erratum in: J Hepatol. 2014 Jun;60(6):1336. Multiple investigator names added.

PMID:
24161408
8.

Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts.

Chan SC, Sharr WW, Chok KS, Chan AC, Lo CM.

Transplantation. 2013 Dec 15;96(11):995-9. doi: 10.1097/TP.0b013e3182a339a7.

PMID:
23924774
9.

Prospective study on the outcome of patients with hepatocellular carcinoma registered for living donor liver transplantation: how long can they wait?

Mizuno S, Yokoi H, Shiraki K, Usui M, Sakurai H, Tabata M, Sugimoto K, Takei Y, Yamakado K, Takeda K, Uemoto S, Isaji S.

Transplantation. 2010 Mar 27;89(6):650-4. doi: 10.1097/TP.0b013e3181cd4ae9.

PMID:
20048691
10.

Section 4. Further expanding the criteria for HCC in living donor liver transplantation: the Tokyo University experience.

Tamura S, Sugawara Y, Kokudo N.

Transplantation. 2014 Apr 27;97 Suppl 8:S17-20. doi: 10.1097/01.tp.0000446268.26771.59.

PMID:
24849823
11.

Should we perform deceased donor liver transplantation after living donor liver transplantation has failed?

Greig PD, Geier A, D'Alessandro AM, Campbell M, Wright L.

Liver Transpl. 2011 Oct;17 Suppl 2:S139-46. doi: 10.1002/lt.22328. Review. No abstract available.

12.

Living donor liver transplantation for hepatocellular carcinoma: current status in Korea.

Lee SG, Moon DB, Shin H, Kim KH, Ahn CS, Ha TY, Song GW, Jung DH, Park GC.

Transplant Proc. 2012 Mar;44(2):520-2. doi: 10.1016/j.transproceed.2012.02.003. No abstract available.

PMID:
22410060
13.

Section 2. Small-for-size liver graft and hepatocellular carcinoma recurrence.

Chan SC.

Transplantation. 2014 Apr 27;97 Suppl 8:S7-S10. doi: 10.1097/01.tp.0000446266.42019.28. Review.

PMID:
24849840
14.

Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.

Kim JM, Kwon CH, Joh JW, Choi MS, Lee JH, Koh KC, Paik SW, Kim GS, Kim SJ, Lee SK, Yoo BC.

Transplant Proc. 2012 Mar;44(2):403-8. doi: 10.1016/j.transproceed.2012.01.067.

PMID:
22410028
15.

Is hepatic transplantation justified for primary liver cancer?

Fisher RA, Maluf DG, Wolfe L, Williams B, Cotterell A, Stravitz RT, Heuman D, Posner M.

J Surg Oncol. 2007 Jun 15;95(8):674-9. Review.

PMID:
17477383
16.

Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?

Grant D, Fisher RA, Abecassis M, McCaughan G, Wright L, Fan ST.

Liver Transpl. 2011 Oct;17 Suppl 2:S133-8. doi: 10.1002/lt.22348. Review. No abstract available.

17.

Hepatocellular carcinoma: resection versus transplantation.

Earl TM, Chapman WC.

Semin Liver Dis. 2013 Aug;33(3):282-92. doi: 10.1055/s-0033-1351783. Review.

PMID:
23943108
18.

Transplantation for hepatocellular carcinoma: the North American experience.

Earl TM, Chapman WC.

Recent Results Cancer Res. 2013;190:145-64. doi: 10.1007/978-3-642-16037-0_10. Review.

PMID:
22941019
19.

Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.

Xiao GQ, Song JL, Shen S, Yang JY, Yan LN.

World J Gastroenterol. 2014 Aug 21;20(31):10953-9. doi: 10.3748/wjg.v20.i31.10953.

20.

Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW.

World J Gastroenterol. 2013 Nov 21;19(43):7515-30. doi: 10.3748/wjg.v19.i43.7515. Review.

Items per page

Supplemental Content

Support Center